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DESIGN: A novel injectable and in situ forming drug depot based on thermally-responsive elastin-like polypeptide (ELP) will be used to deliver an anti-inflammatory drug to an injured joint and provide slow release over time. METHOD(S): Loaded ELP depots were incubated at 37ºC with or without 10% serum to quantify in vitro drug release over 1 week. Drug release was quantified by UV-Vis spectroscopy for serum-free conditions and by commercially available ELISA kits (R&D Systems) in the presence of serum. Bioactivity of released sTNFRII was evaluated via the murine L929 cytoprotection assay, an industry standard. DATA ANALYSIS: Means and SEM (n=4) of released drug were calculated at each time point (1, 2, 3, 24, 48, 72, 96, and 168 hours) , and data were fit to a nonlinear model of one dimensional steady-state diffusion. FINDINGS: Over 7 days, 80% of IL1Ra was released from the ELP depot in serum-free and serum-containing conditions. For sTNFRII, 8% of loaded drug was released from the ELP depot in serum-free conditions, compared to 79% in the presence of serum. These findings confirm the mechanism that drug is released from the degrading drug depot. Released sTNFRII was found to retain activity against TNFα at each time point.
ELP -Elastin-like polypeptide, Drug Depot -technology allowing sustained release of biologically active agent , Active agents used include IL1Ra (anakinra, 150mg/ml), or sTNFRII (etanercept, 25 mg/ml). olson016@mc.duke.edu 
Introduction
We are writing to provide the annual report for the project entitled "Development of Intra-Articular Drug Delivery to Alter Progression Of Arthritis Following Joint Injury". We have recently been granted a no cost extension for this award -approved 05/04/2012. With the no cost extension approval the final report date was moved to April 14, 2013. The current annual report was due April 14, 2012. I apologize for the delay in submission of this annual report. This report was submitted with an included abstract. The abstract has been removed and an appendix has been included.
In brief this protocol explores the use of elastin like polypeptide (ELP) as a sustained delivery vehicle for intra-articular therapy following intra-articular fractures. The ELP used contained IL-1Ra (kineret) or sTNFRII (etanercept) alone or both drugs in combination as active agents.
Body
To date we have accomplished the successful production of sterile ELP depots. The ELP depots were successfully loaded with the drugs IL-1Ra (kineret) and sTNFRII (etanercept). The drug release profiles of IL-1Ra and sTNFRII from the ELP depots were successfully quantified. Closed articular fractures of the tibial plateau were successfully created with an 83% success rate in all mice. Following fracture, intraarticular injections of the ELP depots with IL-1Ra, sTNFRII, IL-1Ra+sTNFRII, and PBS were successfully administered in all mice with no complications or adverse events. All animals were sacrificed at 4 and 8 weeks post-fracture. Serum, synovial fluid and hind limbs were harvested from all animals. Hind limbs from all mice have been formalin fixed. Hind limbs from ELP-IL-Ra, ELP-PBS and age-matched controls have been scanned by microCT, bone morphological analysis is complete, and limbs have been processed and embedded in paraffin. MicroCT scanning and bone morphological analysis of hind limbs from ELPsTNFRII, ELP-IL-1Ra+sTNFRII and fracture with no treatment controls is in progress.
We are requested the no cost extension in order to section and stain histologic sections of hind limbs from ELP-IL-Ra, ELP-PBS, and age-matched control mice; to complete microCT scanning and bone morphological analysis of hind limbs from ELP-sTNFRII, ELP-IL-1Ra+sTNFRII, and fracture with no treatment control mice, followed by histologic processing, paraffin embedding, sectioning, and staining. The outcome from the histologic and bone morphological analyses will be used to assist in selection of biomarkers and cytokines to be assayed immediately following.
The delay in completing these analyses was due to issues in the initial quantification of the drug release profiles from ELP. We wanted to confirm drug release and to develop a reliable protocol for quantifying drug release both in vitro and in vivo. We overcame these technical challenges but quantification of the drug release profile for IL-1Ra from the ELP drug depots was completed in April 2011 and quantification of the drug release profile for sTNFRII from the ELP drug depots was completed by August 2011, later than we had anticipated. Since this initial delay, all other aspects of the project have proceeded as expected, and the scope of the work has not changed. We are progressing with the analysis of the limbs from all mice. Currently Micro-CT imaging is complete. Histologic sectioning is underway for these specimens. Preliminary work to begin biomarker assessment is also in progress.
Key Research Accomplishments
To date the progress with the project is summarized below
Reportable Outcomes
Over 7 days, 80% of IL1Ra was released from the ELP depot in serum-free and serum-containing conditions. For sTNFRII, 8% of loaded drug was released from the ELP depot in serum-free conditions, compared to 79% in the presence of serum. These findings confirm the mechanism that drug is released from the degrading drug depot. Released sTNFRII was found to retain activity against TNFα at each time point.
The IL1-RA delivered intra-articularly via ELP significantly reduced synovitis after intra-articular fracture and had modified Mankin scores that were equal to the non-fracture controls. The prolonged intra-articular inhibition of IL-1 reduced the severity of arthritic changes in both cartilage and joint tissue. However, the inhibition of TNF-α resulted in detrimental bone morphological changes, loss of cartilage, and inflammation of joint tissue. This study shows a novel reduction in post-trauma inflammation that has potential for clinical applications, and provides evidence for an alternate delivery method of anti-inflammatories for joint trauma.
Conclusions
We anticipate completion of the project within the additional year provided through the no cost extension. 
